Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cordis updates catheters

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson subsidiary introduces May 31 its Frontrunner XP CTO and Outback LTD re-entry catheters nationwide to treat lower leg artery blockages. Frontrunner is designed to cross through tough lesions with a jaw-like mechanism to allow balloons or stents to pass, while Outback helps redirect guidewires into the correct path through the plaque. The devices previously were marketed on a smaller scale by Lumend, which Cordis acquired last September (1"The Gray Sheet" Oct. 3, 2005, In Brief). Since the acquisition, Cordis has been ramping up production, as well as making device modifications. Frontrunner is tailored for peripheral use, with more sizes and a stronger radial force. The Cordis version of Outback includes a sharper needle tip and a locking mechanism on the deployment system. The revisions have improved the re-entry success rate with the device from 75% to 94%, according to the firm...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023614

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel